Furthermore, the anti-CD20 antibody rituximab (against malignant B cell neoplasms) [86], as well as the anti-CD38 antibody daratumumab [87] and the anti-CD319 (SLAMF7) antibody elotuzumab [88], which are both part of the treatment arsenal against multiple myeloma, bind to the AR CD16 via their constant Fc portion and to the tumor cells by their variable part specific for the cited tumor antigens. This evidence concerns the gene CD38 and plasma cell myeloma.